CAS: 2001-95-8; Valinomycin

上下游产品

CAS号126784-73-4 TFA.(D-Val-Lac-...

D-Hiv-D-Val-L-Lac-L-Val-Snac 在 Recombinant Terminal Cesb Thioesterase体系中,用 Aq. Buffer作为反应溶剂,反应 14.0H,获得 Valinomycin
参考文献:来自脑脑苷脂生物合成的硫酯酶负责线性四肽的寡聚化和大环化.
标题:来自脑脑苷脂生物合成的硫酯酶负责线性四肽的寡聚化和大环化.
摘要:Cereulide 是一种有毒的环状 Depsidodecapeptide,由两种非核糖体肽合成酶 Cesa 和 Cesb在蜡样芽孢杆菌中产生.虽然在结构上与缬氨霉素高度相似,并具有同源的生物合成基因簇,但最近的工作表明,脑蓝素是通过一种不同的机制产生的,该机制依赖于两个二缩肽-肽基载体蛋白 (Pcp) 结合中间体的非规范偶联.最终,这种替代机制产生了一种四肽-Pcp 结合中间体,它不同于根据 Cesa 和 Cesb 的规范活性预测的四肽-Pcp 中间体.为了区分机制,将两种四肽制备为n-乙酰半胱胺硫酯 (Snac),以及纯化的重组末端 Cesb 硫酯酶 (Cesb Te) 寡聚化和大环化每种底物的能力.只有经典底物被转化为脑脑苷脂,排除了替代机制.结果表明,Cesb Te 可以使用相关的四肽底物,如缬氨霉素四肽和混合脑苷脂-缬氨霉素四肽与其天然底物结合产生嵌合天然产物.这项工作阐明了脑苷
Doi:10.1021/Acs.Jnatprod.0C00333

专利信息

专利号:US-6362009-B1
优先权日:1997-11-21
标 题 :Solid phase synthesis of heterocycles
发明人：MUNOZ BENITO; CHEN CHIXU
权利人:MERCK & CO INC
摘要:Methods for solid phase and combinatorial synthesis using a resin activation/capture approach are provided. In particular, methods for the production of dihydropyridones, N-acyidihydropyridones, tetrahydropyridones, pyridines, aminopyridines, N-acyltetrahydropyridines and tetrahydropyridines compounds and libraries containing such compounds are provided. Methods for screening the libraries and compounds and pharmaceutical compositions containing compounds prepared by the methods are provided.

专利号:US-9989489-B2
优先权日:2006-12-14
标 题 :Methods for calibrating an array of chemically-sensitive sensors
发明人：ROTHBERG JONATHAN; HINZ WOLFGANG; JOHNSON Kim; BUSTILLO JAMES
权利人:LIFE TECHNOLOGIES CORP; LIFE TECHNNOLOGIES CORP
摘要:Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis.

专利号:US-2007060499-A1
优先权日:2005-09-15
标 题 :Chloroquine combination drugs and methods for their synthesis
发明人：KOSAK KENNETH M
权利人:KOSAK KENNETH M
摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

专利号:WO-9845313-A1
优先权日:1997-04-04
标题:Novel uncoupling protein and methods of use
发明人：LARKIN SARAH; MOORE CANDACE; ALBRANDT KEITH; YOUNG ANDREW; BEAUMONT KEVIN
权利人:AMYLIN PHARMACEUTICALS INC; LARKIN SARAH; MOORE CANDACE; ALBRANDT KEITH; YOUNG ANDREW; BEAUMONT KEVIN
摘要:A novel uncoupling protein, which we have designated UCP-3, that is expressed in skeletal muscle and brown adipose tissue (BAT), and nucleic acid molecules which encode for said novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-3 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis or respiratory ATP synthesis is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-3 is also described.

专利号:WO-9520043-A1
优先权日:1994-01-19
标题 :Inhibition of vacuolar h+ -atpase by phosphorothioate oligonucleotides
发明人：STEIN CY A; TONKINSON JOHN L
权利人:UNIV COLUMBIA
摘要:The present invention provides a method of inhibiting vacuolar H+-ATPase activity in a cell which comprises administering to the cell an effective amount of an oligonucleotide which may be substituted or modified in its phosphate, sugar, or base, so as to thereby inhibit the vacuolar H+-ATPase activity. The invention is particularly suited for use as an assay of vacuolar H+-ATPase activity, and use with patients who are suffering from vacuolar H+-ATPase disorders associated with: osteoporosis, increased cholesterol or triglyceride, synthesis or production levels; increased acid secretion from parietal cells; or bone absorption and reabsorption.

专利号:US-6475719-B1
优先权日:1989-04-20
标 题:Determination of factors affecting gene regulation and/or gene replication
发明人：KARP MATTI; KORPELA MATTI
权利人:BIO ORBIT OY
摘要:The invention relates to a method for determining a factor affecting a cell, which affects directly or indirectly the DNA, RNA and/or proteins of the cell or their synthesis machinery, in which recombinant DNA plasmid is transferred into the cell, and the initial point or points of the reproducing machinery responsible for its replication are subject to an adjustable promoter, which is controllable either by positive or negative feedback; the cell containing the recombinant DNA plasmid is brought into contact with the affecting factor; the affecting factor is allowed to affect the cell containing the recombinant DNA plasmid for a suitable time, after which the promoter adjusting the starting point of the reproducing machinery responsible for the replication of the recombinant DNA plasmid starts growing in the cell, unless the affecting factor has not inhibited the replication of the plasmid; the shift of the copy number of the recombinant DNA plasmid in the cell is determined directly or indirectly.